Triple detection of tumor protein p63, Ki-67 and Alpha-methylacyl-CoA racemase in pathological diagnosis of prostate cancer
p63, Ki-67 and Alpha-methylacyl-CoA racemase in diagnosis of prostate cancer
Abstract
Objective: To explore the value and significance of triple immunohistochemical detection of Alpha-methylacyl-CoA racemase (AMACR), p63 and Ki-67 in the pathological diagnosis of prostate cancer.
Methods: A total of 156 paraffin-archived prostate biopsy samples collected from our hospital from June 2023 to August 2024 were selected as research materials. The expression levels of AMACR, p63 and Ki-67 in puncture samples from 48 patients with prostate cancer, 32 patients with high-grade prostate intraepithelial neoplasia, 26 patients with low-grade prostate intraepithelial neoplasia and 50 patients with benign prostatic hyperplasia were detected via immunohistochemistry.
Results: There were statistically significant differences in the positive expression rates of AMACR, p63 and Ki-67 among the different groups of samples. The positive expression rate of AMACR in the puncture samples of the prostate cancer group was 100%, among which the high expression rate was 81.25%. The negative expression rate of p63 was 97.92%, which was significantly greater than that of the other three groups. The positive expression rate of Ki-67 was 81.25%, and the high expression rate was 54.17%. AMACR is related to the long diameter of the tumor, TNM stage, degree of differentiation and Gleason score in patients with prostate cancer. The rates of high AMACR in patients with tumors with long diameters ≥1.5 cm, stage II–III, moderate to highly differentiated, and Gleason scores ranging from 8--10 were significantly higher than those in patients with tumors with long diameters <1.5 cm, stage I. The expression of Ki-67 is related to the long diameter of the tumor, degree of differentiation, degree of lymph node metastasis and Gleason score in patients with prostate cancer. The rate of high expression of Ki-67 in patients with a long tumor diameter of ≥1.5 cm, moderate and high differentiation, lymph node metastasis, and a Gleason score of 8--10 was significantly greater than that in patients with a long tumor diameter of <1.5 cm, poor differentiation, no lymph node metastasis, and a Gleason score of 2--7, respectively. p63 was not related to the clinical or pathological characteristics of patients with prostate cancer (all P>0.05). The sensitivity and negative predictive value of the combined diagnosis of AMACR-positive/ p63-negative/Ki-67-positive prostate cancer were both 100.00%, and the specificity was 81.82%.
Conclusion: AMACR, p63 and Ki-67 in prostate biopsy samples can be used as good biomarkers for the diagnosis or exclusion of prostate cancer. Combined detection can improve the accuracy of prostate cancer diagnosis.
References
2.Rathod SG, Jaiswal DG, Bindu RS. Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain in prostate neoplasm. J Family Med Prim Care. 2019 Aug 28;8(8):2651-2655. doi: 10.4103/jfmpc.jfmpc_432_19. PMID: 31548949; PMCID: PMC6753827.
3.Ramatlho P, Rugemalila MM, Tawe L, Pain D, Choga OT, Ndlovu AK, Koobotse MO, Lal P, Rebbeck TR, Paganotti GM, Narasimhamurthy M, Kyokunda LT. The Role of Immunohistochemistry for AMACR/p504s and p63 in Distinguishing Prostate Cancer from Benign Prostate Tissue Samples in Botswana. Res Rep Urol. 2025 Jan 22;17:1-10. doi: 10.2147/RRU.S492935. PMID: 39872294; PMCID: PMC11766141.
4.Boran C, Kandirali E, Yilmaz F, Serin E, Akyol M. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma. Urol Oncol. 2011 Nov-Dec;29(6):614-23. doi: 10.1016/j.urolonc.2009.11.013. Epub 2010 Mar 2. PMID: 20189848.
5.Ng VW, Koh M, Tan SY, Tan PH. Is triple immunostaining with 34betaE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study. Am J Clin Pathol. 2007 Feb;127(2):248-53. doi: 10.1309/JCFW75KGFWQUHVQD. PMID: 17210521.
6.Yu T, Zhu SX, Zheng S, Chen SP. [Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer]. Zhonghua Nan Ke Xue. 2007 Mar;13(3):222-5. Chinese. PMID: 17393784.
7.Herawi M, Epstein JI. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol. 2007 Jun;31(6):889-94. doi: 10.1097/01.pas.0000213447.16526.7f. PMID: 17527076.
8.Molinié V, Vieillefond A, Michiels JF; pour la commission prostate de l'AFAQAP. Evaluation des marqueurs p63 et p504s dans le diagnostic du cancer de prostate [Evaluation of p63 and p504s markers for the diagnosis of prostate cancer]. Ann Pathol. 2008 Oct;28(5):417-23. French. doi: 10.1016/j.annpat.2008.05.004. Epub 2008 Oct 9. PMID: 19068396.
9.Čamdžić N, Kuskunović-Vlahovljak S, Dorić M, Radović S, Lazović Salčin E, Babić M. Serum total prostate-specific antigen (tPSA): correlation with diagnosis and grading of prostate cancer in core needle biopsy. Med Glas (Zenica). 2021 Feb 1;18(1):122-127. doi: 10.17392/1204-21. PMID: 32815673.
10.McDaniel AS, Chinnaiyan AM, Siddiqui J, McKenney JK, Mehra R. Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3. Am J Surg Pathol. 2014 Dec;38(12):1664-71. doi: 10.1097/PAS.0000000000000267. PMID: 24921643.
11.Hameed O, Humphrey PA. p63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning. Am J Clin Pathol. 2005 Nov;124(5):708-15. doi: 10.1309/JXK1-BVAT-GBVN-Q9J9. PMID: 16203278.
12.Pierconti F, Rossi ED, Martini M, Sacco E, Bassi PF, Larocca LM. 34BetaE12 and Alfa-Methylacyl Coenzyme A Racemase (AMACR) Antibodies Better Than p63 Antibody Distinguish Normal and Neoplastic Glands in Prostatic Tissue With Thermal Artifacts. Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):306-310. doi: 10.1097/PAI.0000000000000599. PMID: 29346181.
13.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
14.Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol. 2004 Dec;35(12):1462-8. doi: 10.1016/j.humpath.2004.09.009. PMID: 15619204.
15.Jiang Z, Li C, Fischer A, Dresser K, Woda BA. Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005 Feb;123(2):231-6. doi: 10.1309/1g1nk9dbgfnb792l. PMID: 15842047.
16.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
17.Singh V, Manu V, Malik A, Dutta V, Mani NS, Patrikar S. Diagnostic utility of p63 and α-methyl acyl Co A racemase in resolving suspicious foci in prostatic needle biopsy and transurethral resection of prostate specimens. J Cancer Res Ther. 2014 Jul-Sep;10(3):686-92. doi: 10.4103/0973-1482.138194. PMID: 25313761.
18.Liu YN, Jiang ZM, Wang XY, Zhang HZ, Chen JQ, Huang J, Yang QH. [The value of using an AMACR/34betaE12/p63 cocktail double staining for diagnosis of prostate carcinoma and precarcinomatous lesions]. Zhonghua Bing Li Xue Za Zhi. 2006 Jul;35(7):417-20. Chinese. PMID: 17069678.
19.Krzyzanowska A, Lippolis G, Helczynski L, Anand A, Peltola M, Pettersson K, Lilja H, Bjartell A. Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections. J Histochem Cytochem. 2016 May;64(5):311-22. doi: 10.1369/0022155416640466. Epub 2016 Mar 29. PMID: 27026295; PMCID: PMC4851272.
20.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
21.Pértega-Gomes N, Vizcaíno JR, Gouveia C, Jerónimo C, Henrique RM, Lopes C, Baltazar F. Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate. 2013 May;73(7):763-9. doi: 10.1002/pros.22620. Epub 2012 Nov 28. PMID: 23192371.
22.Stewart J, Fleshner N, Cole H, Sweet J. Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study. J Clin Pathol. 2007 Jul;60(7):773-80. doi: 10.1136/jcp.2006.040808. Epub 2006 Aug 17. PMID: 16916997; PMCID: PMC1995785.
23.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
24.Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol. 2005 May;29(5):579-87. doi: 10.1097/01.pas.0000157936.93999.18. PMID: 15832080.
25.Kristiansen G, Fritzsche FR, Wassermann K, Jäger C, Tölls A, Lein M, Stephan C, Jung K, Pilarsky C, Dietel M, Moch H. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer. 2008 Sep 16;99(6):939-48. doi: 10.1038/sj.bjc.6604614. PMID: 18781151; PMCID: PMC2538754.
26.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
27.Lindner V, Waydelich A, Chen CC, Jones C, Stratton SP. Performance comparison of anti-p504s (SP116) Rabbit Monoclonal Primary Antibody vs. Monoclonal Rabbit Anti-Human AMACR clone 13H4 when duplexed with VENTANA Basal Cell Cocktail (34βE12+p63) as a diagnostic aid for prostatic adenocarcinoma using immunohistochemistry. Virchows Arch. 2021 Aug;479(2):337-343. doi: 10.1007/s00428-021-03088-4. Epub 2021 Apr 3. PMID: 33811532.
28.Farinola MA, Epstein JI. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum Pathol. 2004 Oct;35(10):1272-8. doi: 10.1016/j.humpath.2004.06.015. PMID: 15492996.
29.Daoud NA, Li G, Evans AJ, van der Kwast TH. The value of triple antibody (34βE12 + p63 + AMACR) cocktail stain in radical prostatectomy specimens with crushed surgical margins. J Clin Pathol. 2012 May;65(5):437-40. doi: 10.1136/jclinpath-2011-200533. Epub 2012 Jan 31. PMID: 22294716.
30.Sircar K, Gaboury L, Ouadi L, Mecteau M, Scarlata E, Saad F, Aprikian A, Tanguay S, Lapointe S, Lussier C, Miletti T, Lanoix J. Isolation of human prostatic epithelial plasma membranes for proteomics using mirror image tissue banking of radical prostatectomy specimens. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4178-84. doi: 10.1158/1078-0432.CCR-06-0328. PMID: 16857789.
Copyright (c) 2025 Ming Niu, Danbo Zhao, Ruixue He, Ling Qin, Zhikai Li, Side Zhang, Lijun Chen
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.